Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Management Strategies for Liver Fibrosis
Journal Information
Vol. 16. Issue 1.
Pages 48-56 (January - February 2017)
Download PDF
More article options
Vol. 16. Issue 1.
Pages 48-56 (January - February 2017)
DOI: 10.5604/16652681.1226814
Open Access
Management Strategies for Liver Fibrosis
Alejandra Altamirano-Barrera*, Beatriz Barranco-Fragoso**, Nahum Méndez-Sánchez
Corresponding author

Correspondence and reprint request:
* Liver Research Unit. Medica Sur Clinic & Foundation, Mexico City, Mexico
** Department of Gastroenterology, National Medical Center “20 Noviembre”, 03229 Mexico, DF, Mexico
Article information
Full Text
Download PDF
Figures (2)

Liver fibrosis resulting from chronic liver injury are major causes of morbidity and mortality worldwide. Among causes of hepatic fibro-sis, viral infection is most common (hepatitis B and C). In addition, obesity rates worldwide have accelerated the risk of liver injury due to nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Also liver fibrosis is associated with the consumption of alcohol, or autoimmune hepatitis and chronic cholangiophaties. The response of hepatocytes to inflammation plays a decisive role in the physiopathology of hepatic fibrosis, which involves the recruitment of both pro- and anti-inflammatory cells such as monocytes and macrophages. As well as the production of other cytokines and chemokines, which increase the stimulus of hepatic stellate cells by activating proinflammatory cells. The aim of this review is to identify the therapeutic options available for the treatment of the liver fibrosis, enabling the prevention of progression when is detected in time.

Key words:
Liver fibrosis
Viral hepatitis
Autoimmune liver diseases
Full Text

Chronic liver disease (CLD) and cirrhosis are major sources of morbidity and mortality in the United States as well as in Mexico.1-3 A recent publication1 point out the importance of CLD and cirrhosis among different ethnic groups in the United States. Non alcoholic fatty liver disease (NAFLD) was the most common cause of cirrhosis in the entire cohort. By ethnicity, NAFLD was the most common cause of cirrhosis in Japanese Americans, Native Hawaiians, and Latinos, accounting for 32% of cases. Also alcoholic liver disease was the major cause of cirrhosis in whites (38.2%), while hepatitis C virus was the most common cause in African Americans (29.8%).

Furthermore, it has been suggested that about 0.1% of the European population is affected by cirrhosis, corresponding to 14-26 new cases per 100,000 inhabitants per year or an estimated 170,000 deaths per year.4

Fibrosis in many organs is produced by a pathological excess in the deposit of extracellular matrix, including collagen types 1 and 2, along with chronic inflammation. In the liver, it is associated with the consumption of alcohol, NAFLD, viral or autoimmune hepatitis, and systemic diseases (Figure 1).5

Figure 1.

Mechanisms of hepatic fibrosis. Liver injury may be caused by multiples factors. These factors in turn induce liver inflammation through different types of cells. Also the oxidative stress, nitrosative stress, and apoptosis. Hepatic stellate cells are the key cells in the process of liver fibrosis. Some factors that regulate HSC activation, proliferation, function, and survival represent important therapeutic targets; likewise, therapies that directly degrade scar and/or promote liver regeneration. NK cells: NKT cells. PDGF: platelet-derived growth factor. CTGF: connective tissue growth factor. TGFβ, TGF-β: transforming growth factor-β. COL1A1: composed of collagen type I alpha 1. COL1A2: composed of collagen type I alpha 2.


The response of hepatocytes to inflammation plays a decisive role in the physiopathology of hepatic fibrosis, which involves the recruitment of both pro- and anti-inflammatory cells such as monocytes and macrophages. These amplify the response throughout the production of other cytokines and chemokines, which increase the stimulus of hepatic stellate cells by activating proinflammatory cells. Fibrogenic cytokines, such as transforming growth factor beta (TGF-β), activated by macrophages facilitate the transdifferentiation of stellate cells to myofibroblasts, which are the main source of production of extracellular matrix.6,7 Understanding these mechanisms has several clinical implications, including the development of therapeutic options that allow us to prevent, stop, or revert the progression of hepatic fibrosis and improve liver function (Figure 2).8 Unfortunately, there is no effective antifibrot-ic treatment approved for human use, and the point at which fibrosis becomes irreversible is not yet recognizable. The formation of regenerative nodules, the development of portal hypertension, and data indicating early hepatic failure are considered irreversible changes. However, it has been proved that in the early stages of fibrosis when the cause has been treated (e.g., hepatitis B or C), regression occurs in at least 70% of patients with the right antiviral management.9,10

Figure 2.

Shows several causes of hepatic fibrosis: viral infection is most common (hepatitis B and C). Nonalcoholic steatohepatitis (NASH). Also liver fibrosis is associated with the consumption of alcohol, or autoimmune hepatitis and chronic cholangiophaties.


The aim of this review is to identify the therapeutic options available for the treatment of this pathology, enabling the prevention of progression when it is detected in time.

Therapeutic Options

The therapeutic intervention points can be classed as: eliminating the stimulus or harmful cause; suppressing hepatic inflammation; interfering in the activation of stellate cells; and promoting the deterioration of extracellular matrix. The most effective way to prevent the formation of fibrosis is by eliminating the stimulus or harmful cause of hepatic damage, but this is not always feasible.

Steroids are most commonly used in treating many liver diseases. An example of this is in the histopathological improvement of liver swelling in patients with autoimmune hepatitis. In fact Czaja and Carpenter have reported a decrease in 53 % of fibrosis score of treated patients during 57 ± 7 months. Those researches also observed an improvement in their histological activity score (61 vs. 32%, P = 0.02). Additionally, they suggested that the conventional corticos-teroid regimens are able to prevent, stabilize, or reverse hepatic fibrosis in up to 80% of patients.11 The molecular mechanisms through corticosteroids exert the anti-fibrotic actions have been reviewed recently by Montaño-Loza, et al.12

Briefly, the effects of corticosteroid therapy in autoimmune hepatitis are to limit tissue injury, reduce the molecular signals for fibrosis, and facilitate degradation of the extracellular matrix.

Regarding to the effect of caffeine on the liver fibrosis. It is known that caffeine is a purine alkaloid, acting through the antagonism of adenosine receptors A1 and A2A, with its main effect being observed at therapeutic concentrations of 10-100 μM. Interestingly Modi, 13 observed in 177 patients with liver fibrosis from different etiologies: 121/177 (68%) had chronic hepatitis C; the remaining patients had chronic hepatitis B (13%), delta hepatitis (3%), non-alcoholic steatohepatitis (11%), primary biliary cirrhosis (2%) or autoimmune hepatitis (3%) that daily caffeine consumption above the 75th percentile for the cohort (308 mg ~2.25 cups of coffee equivalents) was associated with reduced liver fibrosis (OR 0.33, 95% CI: 0.14-0.80, p = 0.015).

In other study, Ruhl and Everhart14 found in the Third US National Health and Nutrition Examination Survey, 1988-1994 by using the ALT activity (> 43 U/L) as a marker of liver injury in subjects at high risk for liver injury (with excessive alcohol consumption, viral hepatitis, iron overload, overweight, or impaired glucose metabolism) elevated ALT activity was in 8.7% of this high-risk population. In unadjusted analysis, lower ALT activity was associated with increasing consumption of coffee (P = 0.001) and caffeine (P = 0.001). Multivariate logistic regression analyses showed that the risk of elevated ALT activity declined with increasing intake of coffee (P for trend = 0.034) and caffeine (P < 0.001). Comparing persons who drank more than 2 cups per day with non coffee drinkers, the odds ratio was 0.56 (95% confidence interval, 0.31-1.0). Comparing persons in the highest caffeine quintile with the lowest, the odds ratio was 0.31 (95% confidence interval, 0.16-0.61). We believed that the consumption of caffeine benefits patients with chronic liver disease possibly via the blockage of adenosine, a strong endogenous regulator of inflammation and tissue repair that limits the extent of fibrosis.15 Caffeine 2A receptors are expressed in stellate cells, and the activation of these receptors promotes collagen production. It is also important to mention that caffeine has an positive effect in patients with hepatic stea-tosis. In fact, we observed a dose-dependent reduction in the consumption of caffeine with increasing severity of st-eatosis in the general population. This effect has been observed in animal models of fatty liver, in which caffeine intake improves insulin resistance and reduces inflammatory cytokine production.16

Ursodeoxycholic acid (UDCA) is a physiologic hy-drophilic dihydroxy bile acid.17 The antifibrotic properties of UDCA have been known for a long time. In fact UDCA is used for treatment of primary biliary cholangitis (PBC) in humans which improves clinical indices and helps delay liver transplantation.18 It is also observed that administration of UDCA to patients with PBC is associated with a considerable decrease in the progress of liver fi-brosis. Corpechot, et al. assessed the effect of UDCA therapy on liver fibrosis progression in PBC by a Markov model the progression rates between early and late histo-logic stages in 103 patients with PBC enrolled in a randomized, double-blind, placebo-controlled trial of UDCA. UDCA therapy was associated with a 5-fold lower progression rate from early stage disease to extensive fibrosis or cirrhosis (7% per year under UDCA vs. 34% per year under placebo, P < 0.002), but was not associated with a significant difference in regression rates (3% per year under both UDCA and placebo). When those investigators assessed at 4 years, the probability of UDCA-treated patients to remain in early stage disease they found a 76% (95% confidence interval: 58%-88%), as compared with 29% (15%-52%) in placebo-group.19 The effect antifibrotic activity of UDCA is complex and involves replacement of endogenous cytotoxic bile acids [chenodeoxycholic (CDCA) and DCA acid] by UDCA a non-cytotoxic bile acid; the mechanism is likely to be competition for active ileal transport.17 Those changes in turn might induce inhibition of free oxygen radical-dependent processes in the liver and by reduction in production of cytokines, in particular of tumor necrosis factor-alpha (TNFcc) and tumor growth factor-beta (TGF(3), inducing apoptosis and coordinating processes of inflammation and fibrogenesis.20,21 The UDCA has shown a beneficial effect, specifically in patients with PBC as we mentioned before.22 Furthermore, NorUDCA, a C23 homolog of UDCA that lacks a methylene group in its side chain is not accumulated in the enterohepatic circulation and does not cause hepato-toxicity after its chronic administration.23 NorUDCA has a clear advantage over its parent compound, UDCA, in improvement of liver pathology. In experiments with Mdr2-knockout mice having advanced cholestatic liver disease including sclerosing cholangitis and biliary fibrosis.24 The administration of norUDCA improved liver damage more effective than UDCA.25 In agreement with authors. We believed that norUDCA increased hydrophilicity that led to a decrease in its cytotoxicity and induction of detoxification pathways and elimination routes for bile acids.

Focusing on immunomodulators, natural killer (NK) cells are part of the innate immune system and represent 50% of the lymphoid hepatic reserve. Their primary function is in defense against infectious agents; however, they can diminish hepatic fibrosis through the inhibition or apoptosis of stellate cells via the retinoic acid pathway.26 The destruction of NK cells leads to the liberation of antifi-brotic cytokines such as interferon-alpha (IFN-cc) and IFN-gamma (IFN-y), which suppress the transcription of genes involved in collagen production. IFN-cc antagonizes the TGF-(3/Smad3 pathway, which suppresses the activation of the collagen type I alpha 2 chain (COL1A2) gene, providing a molecular basis for antifibrotic effects.27 Jeong, demonstrated that the consumption of alcohol had a moderating effect on the antifibrotic effect of NK cells, which could help explain the accelerated formation of fibrotic tissue in patients with liver diseases caused by alcohol.28 There are also studies using animal models where therapeutic options are proposed as ways to promote the survival of NK cells.29,30 However, these approaches have yet to demonstrate a benefit in human.

Other mechanisms thought to be involved in fibrosis involve ligands of receptors of farnesoid X (FXR), a nuclear transcription factor that is activated by conjugating to bile acids. Some studies show that CDCA is an endogenous ligand that plays an important role in the regulation of secretion and bile flow.31 Along with regulating hepato-cyte activation, CDCA has shown an antifibrotic effect in animal models. The administration of 1-10 mg/kg of CDCA for 12 weeks led to a reduction in the expression of collagen type 1, TGF-β, as well as a lower production of tissue metalloproteinases in 90% of mice, together with an inhibition of fibrogenesis in 70-80% of them.32 Furthermore, Mudaliar,33 have reported that use of obeticholic acid (a semisynthetic derivative of CDCA) administered for 6 weeks at doses of 25-50 mg was well tolerated, sensitivity to insulin increased, and there was a decrease in inflammation in the liver and of fibrosis in patients with type 2 diabetes mellitus and fatty liver disease. It appears that this approach can improve the integrity of hepato-cytes. Interestingly, the gut microbiota has recently been shown an effect the size and composition of the bile acid pool throughout the enterohepatic circulation via FXR-dependent mechanisms.34 Furthermore, OCA can increase ileal FGF15 and suppress hepatic CYP7A1 expression in germ-free mice, these results suggest its capacity to reverse their reduced FXR signaling and a potential cross talk between OCA and the gut microbiota.

Endocannabinoids are lipid molecules that act on the cannabinoid receptors CB1 and CB2. An increase in the activity of these receptors is involved in the pathophysiol-ogy of visceral obesity and its complications,35 including diabetes mellitus type 2,36 and in the pathophysiology of fatty liver disease,37 and viral hepatitis.38 Activation of the CB1R receptor induces the expression of profibrotic genes and promotes the formation of hepatic fibrosis. Blocking such a receptor has an opposite effect. However, its inhibition has been linked to adverse neuropsychiatric side effects.

Inducible nitric oxide synthase also stimulates hepatic fibrosis.39 An increase in the activity of this enzyme contributes to the development of alcoholic liver disease,40 the progression of viral hepatitis,41 insulin resistance, and obesity. Cinar,7 introduced a peripheral antagonist of the oral receptor CB1R that accumulates in the liver, where it liberates an inhibitor of nitric oxide synthase. With this dual function, a decrease in the rate of progression of hepatic fibrosis and an attenuation of established fibrosis were found, suggesting a future therapeutic option. Another possible drug is Cenicriviroc, an oral antagonist of the chemokine receptors CCR2/CCR5, which showed an antifibrotic effect in animal models of hepatic and renal fibrosis.42 Currently, there is a phase 2b study (CENTAUR) being conducted on adult patients with NASH and hepatic fibrosis.

Accordingly, antioxidants also play a role in the management of fibrosis and most studies discuss the use of vitamin E and its effect on fibrogenesis. Despite the controversial effects. Sanyal,43 reported on a study in which 247 patients were randomized to receive pioglita-zone (30 mg/day), vitamin E (800 U/day), or a placebo for 96 weeks. Those patients who received vitamin E presented statistically significant improvements in NASH (p = 0.001), and a reduction in aspartate transaminase (AST) levels. The study also found reductions in fatty liver disease (p = 0.005 for vitamin E and p < 0.001 for pioglita-zone), improvements in lobular inflammation (p = 0.02 for vitamin E and p = 0.004 for pioglitazone); however, there was no significant amelioration in the fibrosis scales (p = 0.24 for vitamin E and p = 0.12 for pioglitazone).

Silymarin (from Silybum marianum) is a natural herbal component extracted from cardoon milk. This component has shown antifibrotic activity through the cytoprotection and inhibition of hepatic Küpffer cells. Trappoliere, et al.44 demonstrated that this agent had a dose-dependent inhibition on cell proliferation (p < 0.001), cell motility (p < 0.001), and the synthesis of extracellular matrix components (p < 0.05). In addition, it inhibited the synthesis of IL-1 and IL-8 (p < 0.01). A meta-analysis of 14 studies conducted by Jacobs, et al.45 found no significant effects on mortality reduction, nor any histological improvement.

Other compound that has been suggested as antifibrotic is the pirfenidone (PFD) (5 methyl-1-phenil-2 (1H)-pyridone) has proved antifibrotic and anti-inflammatory properties in a wide number of animal models of fibrosis. PFD effects are mediated in part through inhibition of NF-K-B activation, these mechanisms included inhibition of PDGF, hepatic stellate cells (HSC) proliferation, reduction of TNF-cc and IFN-oc levels and decrease in iNOS/NO induction.46,47 Also, PFD down-regulates TGF-(31, TIMP-1, MMP-2 mRNA and collagen deposition.48,49

Flores-Contreras L, et al.50 Have reported that Pirfenidone for two years benefits chronic hepatitis C patients and improves inflammation, fibrosis and steatosis in higher number of patients as previously shown for 12-months treatment with PFD. Additionally, PFD improved TGF(31 and IL-6 levels and diminished liver expression of anti-fibrogenic receptor CB2. Also it has been suggested that PFD has other potential effects to improve the liver fibrosis. However, we believe that more clinical studies are needed to provide solid evidence for a better understanding of mechanisms involved in the effects of anti-inflammatory and antifibrotic drugs.51

Other cells involved in the pathophysiology of fibrosis are dendritic cells (DC). Connolly, found that the depletion of these cells is related to an increase in the levels of inflammatory mediators responsible for the formation of Fibrosis in liver tissue.52 Dendritic cells represent 25% of hepatic leukocytes, so modulation of their function could be a therapeutic approach for hepatic fibrosis.53 Recently, Rahman and Aloman proposed a potential mechanism for the contribution of DC to fibrogenesis.

They stated that DCs regulate the number and activity of cells involved in the development of fibrosis (such as natural killer cells and CD8+ cells), and tissue remodeling, originally attributed to macrophages/monocytes, may be dependent on DC because of their ontogenetic relationship.54 On the other hand, it has been suggested that DC could play a role in the regression of liver fibrosis.55 Jiao, et al. induced liver injury in a murine model using carbon tetrachloride (CCl4) and evaluated fibrosis regression after cessation of insult in an environment depleted of DC.

Kluwe, et al. demonstrated a role for Jun kinase in inflammatory liver damage.56 Animal models have shown that to antagonize this enzyme might be an option for diminishing the formation of fibrosis. Other experimental anti-inflammatory options have been considered, such as the use of antagonists of lysophosphatidic acid (LPA), which plays a decisive role in multiple systemic diseases, including the formation of fibrosis.57

Furthermore molecules such as multimeric amyloid-P can modify the activation of macrophages attenuating inflammatory pathways. Castaño, et al.58 showed that this factor could stabilize inflammation through the local liberation of interleukin (IL)-10 in fibrotic kidneys of animal models. The antagonist of the protein galectin-3 is another therapeutic approach that is being studied, as this protein is critical for the development of hepatic fibrosis. Traber, et al. demonstrated that inhibiting its action for 8 weeks reduced the production of collagen by at least 50% in an animal model.59 In their study, hepatic biopsies revealed a decrease in the stage of fibrosis as well as a reduction in portal inflammation and ballooning.

Another group of treatments concerns hepatoprotec-tive agents. These include hepatocyte growth factor (HGF), deletions or variations of this factor, and the use of synthetic HGF, growth factors similar to insulin, and caspase inhibitors. HGF shows antifibrotic activity by suppressing the action of TGF-β, inducing the expression of collagenases and inhibiting the apoptosis of stellate cells.60 Other studies in animal models support this antifi-brotic effect.61 Caspase inhibitors represent another group of potential therapeutic agents. Hepatocyte apoptosis is an inflammatory profibrogenic process that increases in patients with alcoholic hepatitis and nonalcoholic fatty liver disease, and it correlates with the severity of the disease and fibrosis. Molecules that block caspases involved in the apoptotic pathway have been developed.62 However, because it has been reported that there might be an increase in the risk of malignancy, some studies with these pharmaceuticals have been stopped. No studies have demonstrated human toxicity. Canbay, et al. found that application of the caspase inhibitor IDN-6556 diminished the incidence of hepatic fibrosis in mice, with lower levels of alanine transaminase (ALT) and liver inflammation.63

Several studies have examined the use of angiotensin-converting enzyme inhibitors. Found in stellate cells, these receptors increase cell proliferation and the release of reactive oxygen species when activated, which stimulates the secretion of fibrogenic cytokines.64 Experimental studies in rats conducted by Yoshiji65 demonstrated that the antagonists of such receptors showed antifibrotic activity. Generally, they are well tolerated, representing a good therapeutic option.

TGF-β is the main cytokine implied in fibrogenesis. When its receptors are blocked, there is an inhibition in the production of extracellular matrix and an acceleration in its degradation. Studies on animals have already proven its benefits. Friedman66 demonstrated the fundamental role of this cytokine in hepatic diseases as well as the possibility of reverting fibrosis in early stages. Studies on cur-cumin have shown that it suppresses the expression of genes encoding TGF-β receptors in activated stellate cells via activation of peroxisome proliferator-activated receptor (PPAR)-gamma, which leads to an interruption in the signaling of TGF-γ.67 Because of concern that inhibiting this tumor suppressor pathway might increase the risk of developing neoplasms, other treatments have been developed with good results, such as the use of integrin antagonists. Wang, 68 that the alpha V beta 6 integrin is linked to fibrogenesis by the activation of TGF-β. Blocking this in-tegrin in mice and humans diminished the progression of fibrosis. Studies on other integrins such as alpha V have shown that pharmacological blocking of this subunit mitigated the development of hepatic and renal fibrosis.69

Antagonists of endothelin receptors are implicated in possible therapies The most studied example is Bosentan, which diminishes the activation of stellate cells and the levels of collagen type 1 protein and of fibronectin mRNA from liver tissues.70 However, besides showing antifibrotic effects in experiments, the risk of hepatotoxicity discourages its regular use.

Cytokine antagonists belong to another pharmacological group formed by the blockers of platelet-derived growth factor (PDGF), blockers of the receptors of vascular endothelial growth factor (VEGF), intracellular cAMP modulators or in some transporters. Yoshiji,71 used an animal model employing double blockage of PDGF and TGF-β; applying Imatinib and angiotensin inhibitors showed a reduction in the development of hepatic fibro-sis. Another example is Sorafenib, a multikinase inhibitor used on patients with hepatocellular carcinomas, which has shown antifibrotic effects in studies with animal models. Hennenberg, 72 showed that rats with hepatic damage administered 60 mg/kg per day for 1 week demonstrated a reduction in the formation of procollagen type 1 alpha, less deposit of perisinusoidal extracellular matrix, and minor activation of stellate cells, leading to lower intrahepatic resistance and reduced hepatic damage. Imatinib is commonly used in the management of leukemia and mesen-chymal tumors, and has been shown to diminish hepatic fibrosis. It acts by antagonizing the tyrosine kinase receptor. Yoshiji, et al.73 used an animal model and found a dose-dependent effect of Imatinib on reducing the proliferation, migration, and activation of stellate cells. However, another study only found improvements on an early stage of fibro-sis with a reduction in the formation of extracellular matrix by 30% (p = 0.0455).74 Because the treatment was not effective on established fibrosis, Imatinib could only be a therapeutic option for early stages of fibrosis.

Matrix degradation is another useful therapeutic objective for organs with a certain stage of fibrosis. Using an animal model, Parsons, 75 demonstrated that a reduction in the degradation of extracellular matrix arose secondary to the expression of tissue inhibitor of metalloproteinase inhibitors (TIMP)-1. TIMP-1 promotes the survival of stellate cells that are key to matrix formation. When blocking the activity of TIMP-1, there was histological evidence of a reduction in the accumulation of collagen. Another study has focused on increasing the degradation of matrix histologically; however, its effectiveness has not yet been proven in human studies.76

Further studies are centered on trying to decrease the activity of stellate cells and to place them in a resting state. Two important studies by Troeger, and Kisseleva, showed in animal models that it is possible to revert the effect of fibrosis by inhibiting the function of stellate cells; however, the effects were still dependent on the implemented agents because the stellate cells reactivated when treatments were stopped. Consequently, ways of stopping the activation of these cells for the long term are still being studied.77,78

There are proposals of models in which apoptosis of stellate cells is encouraged for preventing fibrosis; however, it has not been possible to perform studies in which the loss of cells does not affect functional capacity.79 One study on gliotoxin, a fungal metabolite, proved to stimulate the apoptosis of stellate cells in vitro in an animal mod-el.80 This showed a histological reduction in the stage of the fibrosis thanks to the decreasing activity of stellate cells; nevertheless, there was no improvement on the hepatic function observed. Trebicka, et al.81 conducted an important study with atorvastatin, a statin, in which a dose of 15 mg/kg a day proved to reduce early fibrosis as well as the activation of stellate cells in an animal model. Although a long-term effect was not substantiated, there was a reduction in the expression of profibrotic cytokines, which enabled stellate cells to remain in a resting state with less proliferation and apoptosis. However, there is no evidence from human models to suggest the possibility of clinical recovery with this drug.


A number of therapeutic approaches—many of them still being researched—promise a way to prevent, stop, or revert the progression of hepatic fibrosis. The mechanisms must be clearly understood so that we can establish multidisciplinary approaches (combining mechanisms) to achieve long-term effects safely and efficiently. In the future, models of such combined strategies must be created to establish their safe use in humans. Although there are many therapeutic options, the optimal treatments currently remain unknown. We must also bear in mind that the management of affected patients might need to be individualized, taking into account specific types of liver fibrosis.


  • ALT: alanine transaminase.

  • AST: aspartate transaminase.

  • CDCA: chenodeoxycholic acid.

  • CLD: cronic liver disease.

  • DC: dendritic cells.

  • DCA: eoxycholic acid.

  • FXR: arnesoid X.

  • HGF: hepatocyte growth factor.

  • HSC: hepatic stellate cells.

  • IFN-oc: interferon-alpha.

  • IFN-y: interferon- gamma.

  • IL: interleukin.

  • LPA: lysophosphatidic acid.

  • NAFLD: non alcoholic fatty liver disease.

  • NASH: nonalcoholic steatohepatitis.

  • NK: natural killer.

  • PBC: primary biliary cholangitis.

  • PDGF: platelet-derived growth factor.

  • PFD: pirfenidone.

  • PPAR: peroxisome proliferator-activated receptor.

  • TIMP: tissue inhibitor of metalloproteinase inhibitors.

  • TNFoc: factor-alpha.

  • TGF-P: factor beta.

  • UDCA: ursodeoxycholic acid.

  • VEGF: vascular endothelial growth factor.

WARNING in_array() expects parameter 2 to be array, null given (includes_ws_v2/librerias/html/item.php[209])
WARNING in_array() expects parameter 2 to be array, null given (includes_ws_v2/librerias/html/item.php[209])
WARNING in_array() expects parameter 2 to be array, null given (includes_ws_v2/librerias/html/item.php[209])
WARNING in_array() expects parameter 2 to be array, null given (includes_ws_v2/librerias/html/item.php[209])
WARNING in_array() expects parameter 2 to be array, null given (includes_ws_v2/librerias/html/item.php[209])
WARNING in_array() expects parameter 2 to be array, null given (includes_ws_v2/librerias/html/item.php[209])
WARNING in_array() expects parameter 2 to be array, null given (includes_ws_v2/librerias/html/item.php[209])
WARNING in_array() expects parameter 2 to be array, null given (includes_ws_v2/librerias/html/item.php[209])
WARNING in_array() expects parameter 2 to be array, null given (includes_ws_v2/librerias/html/item.php[209])
Setiawan V.W., Stram D.O., Porcel J., Lu S.C., Le Marchand L., Noureddin M..
Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort.
Hepatology, 64 (2016), pp. 1969-1977
Méndez-Sánchez N., Villa A.R., Chávez-Tapia N.C., Ponciano-Rodríguez G., Almeda-Valdés P., González D., Uribe M..
Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data.
Ann Hepatol, pp. 52-55
Méndez-Sánchez N., Aguilar-Ramírez J.R., Reyes A., Dehesa M., Juárez A., Castañeda B., Sánchez-Avila F., et al.
Etiology of liver cirrhosis in Mexico.
Annals of Hepatology, 3 (2004), pp. 30-33
Zatonski W.A., Sulkowska U., Manczuk M., Rehm J., Boffetta P., Lowenfels LA Vecchia C..
Liver cirrhosis mortality in Europe, with special attention to Central and Eastern Europe.
Eur Addict Res, 16 (2010), pp. 193-201
Sánchez-Valle V., Chávez-Tapia N.C., Uribe M., Méndez-Sánchez N..
Role of oxidative stress and molecular changes in liver fibrosis: a review.
Curr Med Chem, 19 (2012), pp. 4850-4860
Lee Y.A., Wallace M.C., Friedman S.L..
Pathobiology of liver fi-brosis: a translational success story.
Cinar R., Iyer M.R., Liu Z., et al.
Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis.
JCI Insight, 1 (2016), pp. e87336
Ghiassi-Nejad Z., Friedman S.L..
Advances in antifibrotic therapy.
Expert Rev Gastroenterol Hepatol, 2 (2008), pp. 803-816
Marcellin P., Gane E., Buti M., Afdhal N., Sievert W., Jacobson I.M., Washington M.K., et al.
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.
D’Ambrosio R., Aghemo A., Rumi M.G., Ronchi G., Donato M.F., Paradis V., Colombo M., et al.
A morphometric and immunohis-tochemical study to assess the benefit of a sustained viro-logical response in hepatitis C virus patients with cirrhosis.
Hepatology, 56 (2012), pp. 532
Czaja A.J., Carpenter H.A..
Decreased fibrosis during corticos-teroid therapy of autoimmune hepatitis.
J Hepatol, 40 (2004), pp. 646-652
Montano-Loza A.J., Thandassery R.B., Czaja A.J..
Targeting Hepatic Fibrosis in Autoimmune Hepatitis.
Dig Dis Sci, 61 (2016), pp. 3118-3139
Modi A.A., Feld J.J., Park Y., Kleiner D.E., Everhart J.E., Liang T.J., Hoofnagle J.H..
Increased caffeine consumption is associated with reduced hepatic fibrosis.
Hepatology, 51 (2010), pp. 201-209
Ruhl C.E., Everhart J.E..
Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States.
Gastroenterology, 128 (2005), pp. 24
Chan E.S., Montesinos M.C., Fernandez P., Montesinos M.C., Trzaska S., Desai A., Tung C.F., et al.
Adenosine A (2A) receptors play a role in the pathogenesis of hepatic cirrhosis.
Br J Pharmacol, 148 (2006), pp. 1144
Gutiérrez-Grobe Y., Chávez-Tapia N., Sánchez-Valle V., Gavi-lanes-Espinar J.G., Ponciano-Rodríguez G., Uribe M., Méndez-Sánchez N..
High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity.
Ann Hepatol, 11 (2012), pp. 350-355
Hofmann A.F..
Biliary secretion and excretion in health and disease: current concepts.
Ann Hepatol, 6 (2007), pp. 15-27
Angulo P., Batts K.P., Therneau T.M., Jorgensen R.A., Dickson E.R., Lindor K.D..
Long-term ursodeoxycholic acid delays histo-logical progression in primary biliary cirrhosis.
Hepatology, 29 (1999), pp. 644-647
Corpechot C., Carrat F., Bonnand A.M., Poupon R., Poupon R..
The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis.
Hepatology, 32 (2000), pp. 1196-1199
Mas N., Tasci I., Comert B., Ocal R., Mas M.R..
Ursodeoxycholic acid treatment improves hepatocyte ultrastructure in rat liver fibrosis.
World J Gastroenterol, 14 (2008), pp. 1108-1111
Ljubuncic P., Tanne Z., Bomzon A..
Ursodeoxycholic acid suppresses extent of lipid peroxidation in diseased liver in experimental cholestatic liver disease.
Dig Dis Sci, 45 (2000), pp. 1921-1928
Lee J., Belanger A., Doucete J.T., Stanca C., Friedman S., Bach N..
Transplantation trends in primary biliary cirrhosis.
Clin Gastroenterol Hepatol, 5 (2007), pp. 1313
Cohen B.I., Hofmann A.F., Mosbach E.H., Stenger R.J., Rothschild M.A., Hagey L.R., Yoon Y.B..
Differing effect of norursodeoxy-cholic and ursodeoxycholic acid on hepatic histology and bile acid metabolism in rabbit.
Gastroenterology, 91 (1986), pp. 189-197
Wagner M., Trauner M..
Transcriptional regulation of hepatobil-iary transport systems in health and disease: implications for a rationale approach to the treatment of intrahepatic cholestasis.
Ann Hepatol, 4 (2005), pp. 77-99
Wagner M., Trauner M..
Recent advances in understanding and managing cholestasis.
F1000 Res, 19 (2016), pp. 5
Radaeva S., Sun R., Jaruga B., Nguyen V.T., Tian Z., Gao B..
Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners.
Gastroenterology, 130 (2006), pp. 435
Inagaki Y., Nemoto T., Kushida M., Sheng Y., Higashi K., Ikeda K., Kawada N., et al.
Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fi-brosis in mice.
Hepatology, 38 (2003), pp. 890
Jeong W.I., Park O., Gao B..
Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis.
Gastroenterology, 134 (2008), pp. 248
Horani A., Muhanna N., Pappo O., Melhem A., Alvarez C.E., Doron S., Wehbi W., et al.
Beneficial effect of glatiramer acetate (Co-paxone) on immune modulation of experimental hepatic fibro-sis.
Am J Physiol Gastrointest Liver Physiol, 292 (2007), pp. G628
Muhanna N., Abu Tair L., Doron S., Amer J., Azzeh M., Mahamid M., Friedman S., et al.
Amelioration of hepatic fibrosis by NK cell activation.
Zhang Y., Edwards P.A..
FXR signaling in metabolic disease.
Fiorucci S., Antonelli E., Rizzo G., Renga B., Mencarelli A., Ric-cardi L., Orlandi S., et al.
The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis.
Gastroenterology, 127 (2004), pp. 1497
Mudaliar S., Henry R.R., Sanyal A.J., Morrow L., Marschall H.U., Kipnes M., Adorini L., et al.
Efficacy and safety of the far-nesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Gastro-enterology, 145 (2013), pp. 574
Sayin S.I., Wahlstrom A., Felin J., Jäntti S., Marschall H.U., Bam-berg K., Angelin B., et al.
Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist.
Cell Metab, 17 (2013), pp. 225-235
Silvestri C., Di Marzo V..
The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders.
Cell Metab, 17 (2013), pp. 475-490
Jourdan T., Godlewski G., Cinar R., Bertola A., Szanda G., Liu J., Tam J., Han T., et al.
Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes.
Nat Med, 19 (2013), pp. 1132-1140
Méndez-Sánchez N., Zamora-Valdes D., Pichardo-Bahena R., Barredo-Prieto B., Ponciano-Rodriguez G., Bermejo-Martínez L., Chavez-Tapia N.C., et al.
Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease.
He´zode C., Roudot-Thoraval F., Nguyen S., Grenard P., Julien B., Zafrani E.S., Pawlotsky J.M., et al.
Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C.
Hepatology, 42 (2005), pp. 63-71
Karlmark K.R., Weiskirchen R., Zimmermann H.W., Gassler N., Ginhoux F., Weber C., Merad M., et al.
Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis.
Hepatology, 50 (2009), pp. 261-274
Tang Y., Forsyth C.B., Farhadi A., Rangan J., Jakate S., Shaikh M., Banan A., et al.
Nitric oxide-mediated intestinal injury is required for alcohol-induced gut leakiness and liver damage.
Alcohol Clin Exp Res, 33 (2009), pp. 1220-1230
Navarro L.A., Wree A., Povero D., Berk M.P., Eguchi A., Ghosh S., Papouchado B.G., Erzurum S.C., et al.
Arginase 2 deficiency results in spontaneous steatohepatitis: a novel link between innate immune activation and hepatic de novo lipogenesis.
J Hepatol, 62 (2015), pp. 412-420
Lefebvre E., Moyle G., Reshef R., Richman L.P., Thompson M., Hong F., Chou H.L., et al.
Antifibrotic Effects of the Dual CCR2/ CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney fibrosis.
PLoS One, 11 (2016), pp. e0158156
Sanyal A.J., Chalasani N., Kowdley K.V., McCullough A., Diehl A.M., Bass N.M., Neuschwander-Tetri B.A., et al.
Pioglitazone. Vitamin E or placebo for nonalcoholic steatohepatitis.
N Engl J Med, 362 (2010), pp. 1675
Trappoliere M., Caligiuri A., Schmid M., Bertolani C., Failli P., Viz-zutti F., Novo E., Silybin A., et al.
Component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells.
J Hepatol, 50 (2009), pp. 1102
Jacobs B.P., Dennehy C., Ramirez G., Sapp J., Lawrence V.A..
Milk thistle for the treatment of liver disease: a systematic review and meta-analysis.
Am J Med, 113 (2002), pp. 506
Wang F., Wen T., Chen X.Y., Wu H..
Protective effects of pir-fenidone on D-galactosamine and lipopolysaccharide-in-duced acute hepatotoxixity in rats.
Inflamm Res, 57 (2008), pp. 183-188
Tsuchiya H., Kaibori M., Yanagida H., Yokoigawa N., Kwon A.H., Okuma T., Kamiyama Y..
Pirfenidone prevents endotoxin-in-duced liver injury after partial hepatectomy in rats.
J Hepatol, 40 (2004), pp. 94-101
García L., Hernández I., Sandoval A., Salazar A., Garcia J., Vera J., Grijalva G., et al.
Pirfenidone effectively reverses experimental liver fibrosis.
J Hepatol, 37 (2002), pp. 797-805
Di Sario A., Bendia E., Macarri G., Candelaresi C., Taffetani S., Marzioni M., Omenetti A., et al.
The anti-fibrotic effects of pir-fenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha 1(l), TIMP-1 and MMP2.
Dig Liver Dis, 36 (2004), pp. 744-751
Flores-Contreras L., Sandoval-Rodríguez A.S., Mena-Enriquez M.G., Lucano-Landeros S., Arellano-Olivera I., Alvarez-Álvar-ez A., Sanchez-Parada M.G., et al.
Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C.
BMC Gastroenterol, 14 (2014), pp. 131
Chavez-Tapia N.C., Méndez-Sánchez N..
Clinical decisions in hepatology: the pirfenidone case analysis.
Ann Hepatol, 13 (2014), pp. 163-165
Connolly M.K., Bedrosian A.S., Mallen-St Clair J., Mitchell A.P., Ibrahim J., Stroud A., Pachter H.L., et al.
In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha.
J Clin Invest, 119 (2009), pp. 3213
Almeda-Valdes P., Aguilar Olivos N.E., Barranco-Fragoso B., Uribe M., Méndez-Sánchez N..
The Role of Dendritic Cells in fi-brosis Progression in Nonalcoholic Fatty Liver Disease.
Bi-omed Res Int, 2015 (2015), pp. 768071
Rahman A.H., Aloman C..
Dendritic cells and liver fibrosis.
Bio-chim Biophys Acta, 1832 (2013), pp. 998-1004
Jiao J., Sastre D., Fiel M.I., et al.
Dendritic cell regulation of carbon tetrachloride-induced murine liver fibrosis regression.
Hepatology, 55 (2012), pp. 244-255
Kluwe J., Pradere J.P., Gwak G.Y., Mencin A., De Minicis S., Os-terreicher C.H., Colmenero J., et al.
Modulation of hepatic fibro-sis by c-Jun-N-terminal kinase inhibition.
Gastroenterology, 138 (2010), pp. 347
Tigyi G..
Aiming drug discovery at lysophosphatidic acid targets.
Br J Pharmacol, 161 (2010), pp. 241
Castaño A.P., Lin S.L., Surowy TSurowy T., Nowlin B.T., Turlap-ati S.A., Patel T., Singh A., et al.
Serum amyloid P inhibits fibro-sis through Fc gamma R-dependent monocyte-macrophage regulation in vivo.
Sci Transl Med, 1 (2009), pp. 5
Traber P.G., Chou H., Zomer E., Surowy T., Nowlin B.T., Turlapati S.A., Patel T., Singh A., et al.
Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioaceta-mide-induced liver disease.
Ozaki I., Zhao G., Mizuta T Ogawa Y., Hara T., Kajihara S., Hisatomi A., et al.
Hepatocyte growth factor induces colla-genase (matrix metalloproteinase-1) via the transcription factor Ets-1 in human hepatic stellate cell line.
J Hepatol, 36 (2002), pp. 169
Yasuda H., Imai E., Shiota A., Fujise N., Morinaga T., Higashio K..
Antifibrogenic effect of a deletion variant of hepatocyte growth factor on liver fibrosis in rats.
Canbay A., Friedman S., Gores G.J..
Apoptosis: the nexus of liver injury and fibrosis.
Hepatology, 39 (2004), pp. 273
Canbay A., Feldstein A., Baskin-Bey E., Bronk S.F., Gores G.J..
The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse.
J Pharmacol Exp Ther, 308 (2004), pp. 1191
Bataller R., Gäbele E., Schoonhoven R., Morris T., Lehnert M., Yang L., Brenner D.A., et al.
Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proin-flammatory events in liver.
Am J Physiol Gastrointest Liver Physiol, 285 (2003), pp. G642
Yoshiji H., Noguchi R., Ikenaka Y., Kitade M., Kaji K., Tsujimoto T., Uemura M., et al.
Renin-angiotensin system inhibitors as therapeutic alternatives in the treatment of chronic liver diseases.
Curr Med Chem, 14 (2007), pp. 2749-2754
Friedman S.L..
Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications.
Nat Clin Pract Gastroenterol Hepatol, 1 (2004), pp. 98
Zheng S., Chen A..
Disruption of transforming growth factor-beta signaling by curcumin induces gene expression of per-oxisome proliferator-activated receptor-gamma in rat hepatic stellate cells.
Am J Physiol Gastrointest Liver Physiol, 292 (2007), pp. G113
Wang B., Dolinski B.M., Kikuchi N., Leone D.R., Peters M.G., Wein-reb P.H., Violette S.M., et al.
Role of aVb6 integrin in acute biliary fibrosis.
Hepatology, 46 (2007), pp. 1404
Henderson N.C., Arnold T.D., Katamura Y., Giacomini M.M., Rodriguez J.D., McCarty J.H., Pellicoro A., et al.
Targeting of av in-tegrin identifies a core molecular pathway that regulates fibrosis in several organs.
Nat Med, 19 (2013), pp. 1617
Rockey D.C., Chung J.J..
Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogene-sis of wound healing.
J Clin Invest, 98 (1996), pp. 1381
Yoshiji H., Kuriyama S., Noguchi R., Ikenaka Y., Yoshii J., Ya-nase K., Namisaki T., et al.
Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-beta with a combination of imatinib mesylate and ACE inhibitor in rats.
Int J Mol Med, 17 (2006), pp. 899
Hennenberg M., Trebicka J., Kohistani Z., Stark C., Nischalke H.D., Krämer B., Körner C., et al.
Hepatic and HSC-specific sor-afenib effects in rats with established secondary biliary cirrhosis.
Lab Invest, 91 (2011), pp. 241
Yoshiji H., Noguchi R., Kuriyama S., Ikenaka Y., Yoshii J., Ya-nase K., Namisaki T., et al.
Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats.
Am J Physiol Gastrointest Liver Physiol, 288 (2005), pp. G907
Neef M., Ledermann M., Saegesser H., Schneider V., Widmer N., Decosterd L.A., Rochat B., et al.
Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term.
Parsons C.J., Bradford B.U., Pan C.Q., Pan C.Q., Cheung E., Schauer M., Knorr A., Krebs B., et al.
Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats.
Hepatology, 40 (2004), pp. 1106
Siller-López F., Sandoval A., Salgado S., Salazar A., Bueno M., Garcia J., Vera J., et al.
Treatment with human metalloprotein-ase-8 gene delivery ameliorates experimental rat liver cirrhosis.
Gastroenterology, 126 (2004), pp. 1122
Troeger J.S., Mederacke I., Gwak G.Y., Salazar A., Bueno M., Garcia J., Vera J., et al.
Deactivation of hepatic stellate cells during liver fibrosis resolution in mice.
Gastroenterology, 143 (2012), pp. 1073
Kisseleva T., Cong M., Paik Y., Scholten D., Jiang C., Benner C., Iwaisako K., et al.
Myofibroblasts revert to an inactive pheno-type during regression of liver fibrosis.
Proc Natl Acad Sci USA, 109 (2012), pp. 9448
Pinzani M..
Unraveling the spider web of hepatic stellate cell apoptosis.
Gastroenterology, 136 (2009), pp. 2061
Dekel R., Zvibel I., Brill S., Brazovsky E., Halpern Z., Oren R..
Gli-otoxin ameliorates development of fibrosis and cirrhosis in a thioacetamide rat model.
Dig Dis Sci, 48 (2003), pp. 1642
Trebicka J., Hennenberg M., Odenthal M., Shir K., Klein S., Granzow M., Vogt A., et al.
Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells.
Copyright © 2017. Fundación Clínica Médica Sur, A.C.
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos